Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0232487 (abdominal discomfort)
 1,724 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

This work evaluated circulating anti-SWAP IgG1 and IgG4 in patients with active S. mansoni infection before and after PZQ and its correlation to clinical, laboratory and sonographic data. The main complaints was abdominal discomfort, pain, tensmus and bleeding per rectum, which progressive decreased after PZQ. The anti-SWAP IgGI and IgG4 were significantly higher in patients than controls. A progressive significant decrease in the level of circulating anti-SWAP IgG1 after treatment, a decrease of IgG4 three months after treatment and a decrease in the egg count after therapy. But, no significant difference in IgG1 or IgG4 was noticed between male and female patients before and after treatment. No significant difference in IgGI or IgG4 in patients having GIT manifestation and organomegalic patients and/or asymptomatic patient. No significant difference in lgG1 or IgG4 between patients with grade (o), graele (I) and grade (II) periportal fibrosis. The sensitivity of ELISA IgGI was 73.3% and specificity was 80% while ELISA IgG4 was 80%. Enlarged liver and/or spleen, periportal fibrosis, and dilated P.V detected by ultrasonography were more among patients than controls. There was no significant difference in hematological parameters and liver function tests between patients and control groups. So, ELISA is sensitive and specific for IgG1 and IgG4. Anti-SWAP IgG1 and IgG4 is useful means in diagnosis and cure, as well as significant reduction of anti-SWAP IgG1 and IgG4 after treatment. Anti-SWAP IgG1 and IgG4 are parameter for evaluating cure. Follow up of anti-schistosomal IgG1 and IgG4 is useful for assessment of treatment
 ...
PMID:IgG isotypes in schistosomiasis patients before and after praziquantel. 1251 25

Chemotherapy-induced pseudomembranous colitis is most commonly associated with methotrexate and 5-fluorouracil. Methotrexate and mesalazine have also been used for the treatment of psoriasis but the effect of these therapies on the Clostridium difficile carriage in the stool of psoriatic patients has not been studied. Our aim was to detect the presence of C. difficile toxin in patients with psoriasis hospitalized for systemic therapy and in those receiving methotrexate and mesalazine. A total of 58 patients with psoriasis were divided into three groups: group A comprised 30 patients admitted with psoriasis involving >30% body surface area, group B1 comprised 15, psoriatic patients receiving methotrexate (0.3-0.4 mg/kg/week), group B2 included 6 patients receiving mesalazine (50-60 mg/kg/day) while group C comprised of 7 patients (5 on methotrexate, 2 on mesalazine) in whom stool samples were taken twice. Among patients in groups B1 and B2, stool samples were taken after at least 4 weeks of therapy. Detection of C. difficile toxin in stool samples was done using the latex agglutination method. Out of the 58 patients 47 were males and 11 were females. The mean age of the patients was 45+/-2.5 years and the duration of the disease was 3+/-0.9 years. Positive C. difficile toxin was found in a total of 19 patients in all three groups (5 patients in group A, 9 in group B1, 2 in group B2 and 3 in group C). Three patients complained of slight abdominal discomfort and increased frequency of stool, of whom 2 had toxin positive in low titres. The rest of the 17 patients who were positive for C. difficile toxin were asymptomatic. There is a obvious rise in the rate of GIT carriage of C. difficile to a variable degree in patients on methotrexate and mesalazine. However, no clear correlation of the gastrointestinal symptoms with either the presence of toxin or its titre could be established.
 ...
PMID:Clostridium difficile toxin assay in psoriatic patients. 1591 74